Evaluation of the impact of experimentally induced fatigability on motor and cognitive functions. effect of high intensity training on motor and cognitive functions:a pilot randomized controlled trial
NCT ID NCT06219304
First seen Sep 10, 2026 ยท Last updated Sep 10, 2026
Summary
Fatigability is one of the most prevalent disorder in MS followed by walking, balance and cognitive disorders. However, there are few experimental studies on the effects of fatigability on balance and gait hampering the knowledge of causal fatigue-related changes of walking, balance and cognition. Nowadays, instrumented systems such as wearable devices and optoelectronic systems are available and can be used to provide quantitative and objective indexes useful to monitor the changes of gait parameters during a fatiguing performance. (Moreover), instrumented assessment of patients' performances in dual task paradigms can reveal the possible impact of fatigability on cognitive functions. So far, high intensity functional training has been already used in MS to reduce fatigability. However, the true impact of reduced fatigability on walking, balance and cognition has not been assessed after a fatiguing task making impossible to understand the real impact of treatments focusing on fatigability on these functions. Thus, the aims of the present proposal are to assess the: 1) the acute effect of experimentally induced motor fatigability on walking, balance and cognitive functions using an objective instrumented assessment before, during, and after an overground fatiguing walking test. 2) to investigate the effect of high intensity multimodal functional training to improve motor and cognitive disorders.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * More than 18 years of age * Clinical diagnosis of Multiple Sclerosis (MS) * Stable disease course without worsening more than 1 EDSS point over the last 3 months, -EDSS between 1.5 and 6 points * Must be able to maintain upright posture without any assistance for 30 seconds * Must be able to release a written informed consent. Exclusion Criteria: * MS relapse within the previous three months; * Unable to comprehend the aims of the study and to follow test instructions; * Diagnosis of major depression (DSM-5); * Severe joint and/or bone disorders interfering with balance and gait (based upon clinical judgment); * Cardiovascular diseases; * Unconfirmed or uncertain diagnosis of MS (McDonald criteria) * Other concomitant neurological disease; * Patients already performing aerobic or walking exercise.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Don Carlo Gnocchi
Milan, MI, 20148, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simulator-Based assessment of driving performance in patients with Parkinson's disease and multiple sclerosis
- Contrasting chronic inflammation and neurodegeneration using the human amniotic mesenchymal cell secretome as an innovative therapeutic strategy
- VIGIP-SEP2: evaluation of the impact of the training of patients by nurses on the adverse drug reaction reporting by RRMS patient via a mobile application: a randomized real-life study
- Five-second sprints on a bike: a new test for multiple sclerosis symptoms
- A new way to gauge balance training intensity in MS?
- A PET tracer aims to reveal the brain inflammation MRI misses in MS